Based on the presentation on 03.05.2016, the estimated top line results for phase II is due late 2018 (subject to change). You can find more details here:
http://actinogen.com.au/wp-content/uploads/2016/05/Investor-Presentation-03-May-2016.pdf
Also, they will start recruiting early 2017 for diabetes cognitive impairment in early 2017. with results around late 2018 as well. I guess these would be best case scenarios.
Ann: Xanamem & AIBL to showcase Cortisol Hypothesis in Alzheimers-ACW.AX, page-12
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.57M | |||
| Open | High | Low | Value | Volume |
| 2.6¢ | 2.7¢ | 2.5¢ | $59.07K | 2.276M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2152913 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 6707443 | 10 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| ACW (ASX) Chart |